Citations

Clear

9 citation(s) found for "Jia, Lin".

Thirty-Six-Month Multicentre Outcomes of Combined Phacoemulsification and Hydrus Microstent Implantation in Eyes With Normal Tension Glaucoma
Ang, Bryan Chin Hou, Sim, Jackie Jia Lin , Chua, Chun Hau, Khairy, Thomas, Salimi, Ali , Harasymowycz, Paul , Ang, Bryan Chin Hou , Ang, Bryan C H , Salimi, Ali , Betzler, Bjorn Kaijun , Ramanathan, Rajesh, Hong, Ashley Shuen Ying

Mayo Clinic

Journal of Glaucoma | March 26, 2026 | Volume: 35 | Issue: 6 | Pages: 369-376

10.1097/ijg.0000000000002709 | PMID 41934671 Get It

Precis: This retrospective multicentre study of 77 NTG eyes undergoing phacoemulsification and Hydrus implantation showed a sustained reduction in medication burden, while maintaining IOP levels. Complications were rare and nonsight-threatening. Purpose: To evaluate 36-month outcomes of combined phacoemulsification and Hydrus Microstent implantation (Phaco-Hydrus) in eyes with normal tension glaucoma (NTG). Methods: This multicentre retrospective study included 77 NTG eyes from Singapore and Canada that underwent Phaco-Hydrus between 2014 and 2023. Primary outcomes were changes in intraocular pressure (IOP) and medication burden, and cumulative success probabilities from Kaplan-Meier (KM) analyses. Longitudinal changes were analysed using generalized estimating equations. Results: Of 77 eyes, 31 completed 36 months of follow-up. Mean baseline IOP and medications was 13.5±2.5 mm Hg and 1.7±0.9, respectively. No significant reductions in IOP were observed. A sustained reduction in medication use was observed at all follow-up timepoints ( P ≤0.001). At 36 months, medication use decreased by −0.7±0.2 [adjusted mean difference±SE of the mean [SEM]]. Proportion of medication-free eyes increased from 7.8% (n=6/77) at baseline to 45.2% (n=14/31) at 36 months. Cumulative success probabilities varied widely based on definitions. When defined as a decrease in ≥1 medication from baseline without an increase in IOP, or IOP ≤15 mm Hg and reduced ≥20% from baseline while medication-free, and no additional laser or incisional glaucoma surgery, this was 40.7% at 36 months. No visual field mean deviation progression was detected. Adverse events were infrequent and nonsight-threatening. Conclusion: In eyes with NTG, Phaco-Hydrus may offer a greater role in medication reduction or achieving a medication-free status over 36 months, rather than absolute IOP reduction.
Trabeculectomy Bleb Characteristics in Relation to Bleb Success Using Anterior Segment Optical Coherence Tomography–A Systematic Review and Meta-Analysis
Sim, Jackie Jia Lin , Betzler, Bjorn Kaijun , Dorairaj, Syril , Dada, Tanuj , Ang, Bryan Chin Hou , Betzler, Bjorn K , Ang, Bryan C H

Mayo Clinic

Journal of Glaucoma | May 14, 2025 | Volume: 34 | Issue: 9 | Pages: 679-687

10.1097/ijg.0000000000002595 | PMID 40838860 Get It

Précis: ASOCT features of greater bleb height, thicker bleb walls, and lower reflectivity are associated with trabeculectomy success, supporting the ASOCT’s utility in monitoring and predicting outcomes postsurgery through standardized imaging protocols. Purpose: To evaluate and quantify the relationship between bleb characteristics on ASOCT with surgical outcomes. Methods: A literature search was conducted across Medline, Embase, Cochrane, and Scopus for studies from the past 20 years, until 16 September 2024, on “glaucoma,” “trabeculectomy,” and “ASOCT.” Data collected included patient characteristics, each study’s definition of bleb success, clinical outcomes, as well as bleb characteristics. A literature review was conducted on studies that could not be used for meta-analysis. Results: Eleven studies, with a pooled total of 528 eyes in 517 patients, were included in the final meta-analysis. Successful blebs had significantly higher mean bleb height [mean difference (MD) 0.38 mm, 95% CI: 0.20-0.56 mm, P=0.002], greater maximum bleb wall thickness (MD: 0.21 mm, 95% CI: 0.07-0.35 mm, P=0.009), and decreased reflectivity (MD: −48.9%, 95% CI: −78.3 to −19.4%, P=0.010), compared with failed blebs. No significant differences were found in bleb fluid cavity height and bleb area. Narrative synthesis revealed that wider blebs, increased fluid-filled cavity height, increased number of microcysts, larger filtration opening widths, and multiform bleb walls were also associated with higher rates of bleb success. Early bleb parameters were statistically significant predictors of bleb success up to 12 months postoperatively. Conclusions: Greater bleb height, thicker bleb walls, and lower reflectivity on ASOCT are consistently associated with successful trabeculectomy outcomes. The ASOCT may be useful in predicting bleb success and in supplementing postoperative monitoring, hence guiding timely medical or procedural interventions, to ensure long-term bleb success.
An international multi-institution real-world study of the optimal surveillance frequency for stage II/III gastric cancer: the more, the better?
Lü, Jun, Lin, Jia, Xu, Binbin , Xue, Zhen , Zheng, Hua‐Long , Lin, Guosheng, Huang, Jiao-bao, Shen, Li-li, Zheng, Chao‐Hui , Li, Ping , Cao, Long‐Long, Ma, Yu‐Bin , Truty, Mark J. , Huang, Chang-Ming, Wu, Dong , Lin, Jia, Huang, Jiao-bao, Shen, Li-li, Xie, Jian‐Wei , Wang, Jia-Bin , Lin, Jian‐Xian , Chen, Qi‐Yue , Huang, Chang-Ming

Mayo Clinic

International Journal of Surgery | October 6, 2023 | Volume: 109 | Issue: 12 | Pages: 4101-4112

10.1097/js9.0000000000000731 | PMID 37800589 Get It

Background: Due to lacking evidence on surveillance for gastric cancer (GC), this study aimed to determine the optimal postsurgical surveillance strategy for pathological stage (pStage) II/III GC patients and compare its cost-effectiveness with traditional surveillance strategies. Methods: Prospectively collected data from stage II/III GC patients (n=1661) who underwent upfront surgery at a large-volume tertiary cancer center in China (FJMUUH cohort) between January 2010 and October 2015. For external validation, two independent cohorts were included, which were composed of 380 stage II/III GC patients at an tertiary cancer center in U.S.A (Mayo cohort) between July 1991 and July 2012 and 270 stage II/III GC patients at another tertiary cancer center in China (QUAH cohort) between May 2010 and October 2014. Random forest models were used to predict dynamic recurrence hazards and to construct individual surveillance strategies for stage II/III GC. Cost-effectiveness was assessed by the Markov model. Results: The median follow-up period of the FJMUUH, the Mayo, and QUAH cohorts were 55, 158, and 70 months, respectively. In the FJMUUH cohort, the 5-year recurrence risk was higher in pStage III compared with pStage II GC patients (P<0.001). Our novel individual surveillance strategy achieved optimal cost-effectiveness for pStage II GC patients (ICER =$490/QALY). The most intensive NCCN surveillance guideline was more cost-effective (ICER =$983/QALY) for pStage III GC patients. The external validations confirmed our results. Conclusion: For patients with pStage II GC, individualized risk-based surveillance outperformed the JGCTG and NCCN surveillance guidelines. However, the NCCN surveillance guideline may be more suitable for patients with pStage III GC. Even though our results are limited by the retrospective study design, the authors believe that our findings should be considered when recommending postoperative surveillance for stage II/III GC with upfront surgery in the absence of a randomized clinical trial.
Novel Wnt modulators for the treatment of Alzheimer’s disease
Li, Yonghe , Macyczko, Jesse R. , Wang, Na , Jia, Lin , Shue, Francis , Lü, Wenyan, Martens, Yuka A. , Shue, Francis , Caulfield, Thomas R. , Zhao, Jing , Liu, Chia‐Chen , Bu, Guojun

Mayo Clinic

Alzheimer's & Dementia | December 20, 2022 | Volume: 18 | Issue: S10 | Pages: No page available

10.1002/alz.063223 Get It

AbstractBackgroundAlzheimer’s disease (AD) is the most common form of age‐related dementia characterized by the presence of amyloid‐β (Aβ) and tau pathologies leading to neurodegeneration and cognitive impairment. Wnt/β‐catenin signaling modulates multiple pathophysiological processes including synaptic plasticity, neuronal survival, neuroinflammation, Aβ production and tau phosphorylation, but this signaling pathway is greatly inhibited in the AD brain. Notably, two SNPs and an alternative splice variant of Wnt co‐receptor LRP6, which result in down‐regulation of Wnt/β‐catenin signaling, are associated with increased risk of developing AD. In addition, apoE4, the strongest risk factor of late‐onset AD, interacts with and decreases cell surface abundance of LRP6 in astrocytes. Studies from our laboratory have demonstrated that the level of LRP6 is significantly downregulated in human AD brains, and that deficiency in LRP6‐mediated Wnt/β‐catenin signaling leads to synaptic abnormalities and amyloid pathology in amyloid model mice. Therefore, LRP6 is an attractive therapeutic target for restoring Wnt/β‐catenin signaling in the AD brain.MethodIn our previous studies, we have discovered niclosamide, an FDA‐approved anthelminthic drug, inhibits Wnt/β‐catenin signaling via promoting LRP6 degradation. Herein, we demonstrated that CI‐994, an analog of niclosamide, exhibits opposite effects on LRP6 level and Wnt/β‐catenin signaling. Following structural optimization, we have generated a series of novel potent Wnt modulators.ResultThe leading compound W2A‐16 displays a good pharmacokinetic profile with high oral bioavailability and brain penetration. Importantly, W2A‐16 significantly activates Wnt/β‐catenin signaling and inhibits tau phosphorylation in AD patient‐specific iPSC‐derived cerebral organoids. Moreover, W2A‐16 attenuates amyloid pathology and gliosis and improves cognitive function in 5xFAD amyloid model mice. Further, W2A‐16 suppresses tau phosphorylation and neuroinflammation, attenuates body weight loss, and improves the survival of PS19 tauopathy mice.ConclusionTogether, these findings demonstrate that W2A‐16 is a strong drug candidate for AD therapy.
APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia
Liu, Chia‐Chen , Murray, Melissa E. , Li, Xia , Zhao, Na , Wang, Na , Shue, Francis , Martens, Yuka A. , Li, Yonghe , Raulin, Ana‐Caroline , Rosenberg, Cassandra L. , Doss, Sydney V. , Wren, Melissa C. , Jia, Lin , Ren, Yingxue , Ikezu, Tadafumi C. , Lü, Wenyan, Trottier, Zachary A. , Chen, Yixing , Linares, Cynthia , Wang, Xue , Kurti, Aishe, Asmann, Yan W. , Vemuri, Prashanthi , Kantarci, Kejal , Lowe, Val J. , Jack, Clifford R. , Parisi, Joseph E., Ferman, Tanis J. , Graff‐Radford, Neill R. , Petersen, Ronald C. , Younkin, Steven G. , Fryer, John Denis , Frieden, Carl , Ross, Owen A. , Bu, Guojun , Shue, Francis , Atagi, Yuka , Raulin, Ana-Caroline , Doss, Sydney V , Zhao, Jing , Wren, Melissa C , Ikezu, Tadafumi C , Caulfield, Thomas R , Trottier, Zachary A , Wszolek, Z.K. , Smith, Glenn E. , Vemuri, Prashanthi , Jack, Clifford R , Ferman, Tanis J , Boeve, Brad , Petersen, Ronald C , Younkin, Steven , Frieden, Carl , Dickson, Dennis W , Ross, Owen A , Bu, Guojun , Liu, Chia-Chen , Kantarci, Kejal , Murray, Melissa E , Zhao, Na , Chen, Yixing , Heckman, Michael G. , Zhao, Jing , Fu, Yuan , Caulfield, Thomas R. , Knight, Joshua A. , Wszołek, Zbigniew K. , Knopman, David S. , Boeve, Bradley F. , Wang, Hu , Han, Xianlin , Dickson, Dennis W.

Mayo Clinic

Science Translational Medicine | September 29, 2021 | Volume: 13 | Issue: 613 | Pages: No page available

10.1126/scitranslmed.abc9375 | PMID 34586832 Get It

A rare APOE variant APOE3 -Jac reduces self-aggregation and promotes healthy brain aging.
Tau and apolipoprotein E modulate cerebrovascular tight junction integrity independent of cerebral amyloid angiopathy in Alzheimer's disease
Liu, Chia‐Chen , Martens, Yuka A. , Jia, Lin , Yamazaki, Akari, Diehl, Nancy N. , Zhao, Na , DeTure, Michael , Davis, Mary Dabney , Felton, Lindsey M., Qiao, Wenhui , Li, Yonghe , Li, Hongmei , Wang, Na , Wren, Melissa C. , Aikawa, Tomonori , Holm, Marie‐Louise , Allen, Mariet , Carrasquillo, Minerva M. , Murray, Melissa E. , Petersen, Ronald C. , Ertekin‐Taner, Nilüfer , Kanekiyo, Takahisa , Bu, Guojun , Wren, Melissa, Oue, Hiroshi , Linares, Cynthia , Liu, Chia-Chen , Bu, Guojun , Murray, Melissa E , Zhao, Na , Yamazaki, Yu , Heckman, Michael G. , Zhao, Jing , Davis, Mary D., Fu, Yuan , Oue, Hiroshi, Carrasquillo, Minerva M. , Dickson, Dennis W.

Mayo Clinic

Alzheimer's & Dementia | August 22, 2020 | Volume: 16 | Issue: 10 | Pages: 1372-1383

10.1002/alz.12104 | PMID 32827351 Get It

AbstractIntroductionCerebrovascular pathologies including cerebral amyloid angiopathy (CAA) and blood‐brain barrier (BBB) dysregulation are prominent features in the majority of Alzheimer's disease (AD) cases.MethodsWe performed neuropathologic and biochemical studies on a large, neuropathologically confirmed human AD cohort (N = 469). Amounts of endothelial tight junction proteins claudin‐5 (CLDN5) and occludin (OCLN), and major AD‐related molecules (amyloid beta [Aβ40], Aβ42, tau, p‐tau, and apolipoprotein E) in the temporal cortex were assessed by ELISA.ResultsHigher levels of soluble tau, insoluble p‐tau, and apolipoprotein E (apoE) were independently correlated with lower levels of endothelial tight junction proteins CLDN5 and OCLN in AD brains. Although high Aβ40 levels, APOE ε4, and male sex were predominantly associated with exacerbated CAA severity, those factors did not influence tight junction protein levels.DiscussionRefining the molecular mechanisms connecting tau, Aβ, and apoE with cerebrovascular pathologies is critical for greater understanding of AD pathogenesis and establishing effective therapeutic interventions for the disease.
Activation of FAK/Rac1/Cdc42‐GTPase signaling ameliorates impaired microglial migration response to Aβ 42 in triggering receptor expressed on myeloid cells 2 loss‐of‐function murine models
Rong, Zhouyi , Cheng, Baoying, Zhong, Li , Jia, Lin , Li, Yanfang , Shue, Francis , Wang, Na , Cheng, Yiyun , Huang, Xiaohua , Liu, Chia‐Chen , Fryer, John Denis , Wang, Xin , Zhang, Yun‐wu , Zheng, Honghua , Liu, Chia-Chen , Shue, Francis , Ye, Xiaowen , Li, Xin , Wang, Na

Mayo Clinic

The FASEB Journal | July 29, 2020 | Volume: 34 | Issue: 8 | Pages: 10984-10997

10.1096/fj.202000550rr | PMID 32613609 Get It

Abstract Mutation of Triggering receptor expressed on myeloid cells 2 (TREM2) impairs the response of microglia to amyloid‐β (Aβ) pathology in Alzheimer's disease (AD), although the mechanism governing TREM2‐regulated microglia recruitment to Aβ plaques remains unresolved. Here, we confirm that TREM2 mutation attenuates microglial migration. Then, using Trem2 −/− mice and an R47H variant mouse model for AD generated for this study, we show that TREM2 deficiency or the AD‐associated R47H mutation results in inhibition of FAK and Rac1/Cdc42‐GTPase signaling critical for cell migration. Intriguingly, treatment with CN04, a Rac1/Cdc42‐GTPase activator, partially enhances microglial migration in response to oligomeric Aβ 42 in Trem2 −/− or R47H microglia both in vitro and in vivo. Our study shows that the dysfunction of microglial migration in the AD‐associated TREM2 R47H variant is caused by FAK/Rac1/Cdc42 signaling disruption, and that activation of this signaling ameliorates impaired microglial migration response to Aβ 42 , suggesting a therapeutic target for R47H‐bearing patients with high risk of AD.
Soluble TREM2 induces inflammatory responses and enhances microglial survival
Zhong, Li , Chen, Xiao‐Fen , Liao, Chunyan , Huang, Ruizhi, Wang, Daxin , Wu, Linbei, Jia, Lin , Zheng, Honghua , Painter, Meghan M. , Atagi, Yuka, Liu, Chia‐Chen , Zhang, Yun‐wu , Fryer, John Denis , Xu, Huaxi , Bu, Guojun , Painter, Meghan , Atagi, Yuka , Liu, Chia-Chen , Fryer, John D., Wang, Tingting , Wang, Zhe , Wang, Zongqi , Li, Xinxiu , Bu, Guojun

Mayo Clinic

Journal of Experimental Medicine | February 16, 2017 | Volume: 214 | Issue: 3 | Pages: 597-607

10.1084/jem.20160844 | PMID 28209725 Get It

Triggering receptor expressed on myeloid cells 2 (TREM2) is an innate immune receptor expressed in microglia in the brain. A soluble form of TREM2 (sTREM2) derived from proteolytic cleavage of the cell surface receptor is increased in the preclinical stages of AD and positively correlates with the amounts of total and phosphorylated tau in the cerebrospinal fluid. However, the physiological and pathological functions of sTREM2 remain unknown. Here, we show that sTREM2 promotes microglial survival in a PI3K/Akt-dependent manner and stimulates the production of inflammatory cytokines depending on NF-κB. Variants of sTREM2 carrying AD risk-associated mutations were less potent in both suppressing apoptosis and triggering inflammatory responses. Importantly, sTREM2 delivered to the hippocampi of both wild-type and Trem2-knockout mice elevated the expression of inflammatory cytokines and induced morphological changes of microglia. Collectively, these data indicate that sTREM2 triggers microglial activation inducing inflammatory responses and promoting survival. This study has implications for the pathogenesis of AD and provides insights into targeting sTREM2 pathway for AD therapy.
Epidermal Growth Factor Receptor Variant III Status Defines Clinically Distinct Subtypes of Glioblastoma
Pelloski, Christopher E., Furth, Alfred, Zhang, Li , Sulman, Erik P. , Bhat, Krishna , McDonald, J. Matthew , Yung, W.K. Alfred, Colman, Howard , Woo, Shiao Y. , Heimberger, Amy B. , Suki, Dima , Prados, Michael D. , Chang, Susan M. , Barker, Fred G., Buckner, Jan C. , James, C. David , Aldape, Kenneth , Ballman, Karla V. , Lin, Eileen Eng Jia , Colman, Howard , Heimberger, Amy B. , Chang, Susan Marina , Sulman, Erik P

Mayo Clinic

Journal of Clinical Oncology | May 30, 2007 | Volume: 25 | Issue: 16 | Pages: 2288-2294

10.1200/jco.2006.08.0705 | PMID 17538175 Get It

Purpose The clinical significance of epidermal growth factor receptor variant III (EGFRvIII) expression in glioblastoma multiforme (GBM) and its relationship with other key molecular markers are not clear. We sought to evaluate the clinical significance of GBM subtypes as defined by EGFRvIII status. Patients and Methods The expression of EGFRvIII was assessed by immunohistochemistry in 649 patients with newly diagnosed GBM. These data were then examined in conjunction with the expression of phospho-intermediates (in a subset of these patients) of downstream AKT and Ras pathways and YKL-40 as well as with known clinical risk factors, including the Radiation Therapy Oncology Group's recursive partitioning analysis (RTOG-RPA) class. Results The RTOG-RPA class was highly predictive of survival in EGFRvIII-negative patients but much less predictive in EGFRvIII-positive patients. These findings were seen in both an initial test set (n = 268) and a larger validation set (n = 381). Similarly, activation of the AKT/MAPK pathways and YKL-40 positivity were predictive of poor outcome in EGFRvIII-negative patients but not in EGFRvIII-positive patients. Pair-wise combinations of markers identified EGFRvIII and YKL-40 as prognostically important. In particular, outcome in patients with EGFRvIII-negative/YKL-40–negative tumors was significantly better than the outcome in patients with the other three combinations of these two markers. Conclusion Established prognostic factors in GBM were not predictive of outcome in the EGFRvIII-positive subset, although this requires confirmation in independent data sets. GBMs negative for both EGFRvIII and YKL-40 show less aggressive behavior.